In planning clinical trials, it is common to find that the calculated sample size1 (Item 7 of the CONSORT checklist; Box 1) is too large for available resources. Strategies to determine whether the trial question(s) can be answered with fewer subjects are needed. These include:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW.
Correspondence: enquiry@ctc.usyd.edu.au
- 1. Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Med J Aust 2002; 177: 256-257. <eMJA full text>
- 2. Miettinen TA, Huttunen JK, Naukkarinen V, et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence and mortality. JAMA 1985; 254: 2097-2102.
- 3. Pablos-Méndez A, Barr G, Shea S. Run-in periods in randomized trials. Implications for the application of results in clinical practice. JAMA 1998; 279: 222-225.
- 4. Gebski V, Marschner I, Keech AC. Specifying objectives and outcomes for clinical trials. Med J Aust 2002; 176: 491-492. <eMJA full text>
- 5. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the on-going Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
- 6. Simes RJ, Topol EJ, Holms DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91: 1923-1928.
Online responses are no longer available. Please refer to our instructions for authors page for more information.